What is NDC 70121-2484?

70121-2484 is the product NDC for Boruzu (bortezomib), Bortezomib 3.5 mg/1.4mL injection, listed with the FDA by Amneal Pharmaceuticals LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

Amneal Pharmaceuticals LLC, NDC labeler code 70121. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Boruzu?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Boruzu NDC 70121-2484 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)70121-2484Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70121-2484Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70121-2484-1	7012124840170121248401	1 VIAL, SINGLE-DOSE in 1 CARTON (70121-2484-1) / 1.4 mL in 1 VIAL, SINGLE-DOSEMarketed from Sep 27, 2024

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Boruzu
Generic name (nonproprietary): bortezomib
Active ingredients: Bortezomib — 3.5 mg/1.4mL
Dosage form: Injection
Route: Intravenous, Subcutaneous
Labeler: Amneal Pharmaceuticals LLCNDC labeler code 70121
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 212782
Marketing start: Sep 27, 2024
Listing expires: Dec 31, 2027
Other FDA classes: Proteasome Inhibitors (Mechanism)
Identifiers: Product ID 70121-2484_6fb2ce70-c98f-4e46-9b0f-6aec0530f61dSPL ID 6fb2ce70-c98f-4e46-9b0f-6aec0530f61dSPL set ID b92628dd-fa09-4c3a-b6a3-66426025807cRxCUI 2608948, 2693996UNII 69G8BD63PPUPC 0370121248415
Pharmacologic class: Proteasome Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N470121248401 followed by a unit qualifier and the quantity

Package 70121-2484-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 5, 2025.

Indications (excerpt from the label)

BORUZU is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma BORUZU is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma BORUZU is indicated for the treatment of adult patients with mantle cell lymphoma.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 70121-2484

What is NDC 70121-2484?: 70121-2484 is the product NDC for Boruzu (bortezomib), Bortezomib 3.5 mg/1.4mL injection, listed with the FDA by Amneal Pharmaceuticals LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Boruzu (Bortezomib).
What is the active ingredient?: Bortezomib.
Who is the labeler?: Amneal Pharmaceuticals LLC, NDC labeler code 70121. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Boruzu?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other NDCs under NDA 212782

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 212782
Product	Strength	Form · route	Labeler	Product NDC
Bortezomib	Bortezomib 3.5 mg/1.4mL	InjectionIntravenous, Subcutaneous	Shilpa Medicare Limited	63759-3032

Boruzu (Bortezomib) NDC 70121-2484